EMA has issued the recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2023.

Manufacturers of egg-based or live attenuated quadrivalent vaccines for the 2023-2024 season should include these three virus strains:

• an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
• an A/Darwin/9/2021 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Manufacturers of cell-based quadrivalent vaccines for the 2023-2024 season should include these three virus strains:

• an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
• an A/Darwin/6/2021 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus

For vaccine manufacturers considering the use of one B lineage vaccine virus only in trivalent vaccines, a B/Austria/1359417/2021 (B/Victoria lineage)-like virus is considered appropriate for inclusion. Therefore, a B/Yamagata lineage virus is not recommended for…